Theravance reports positive Phase II trial results of fibromyalgia drug candidate

US-based biopharmaceutical firm Theravance has revealed positive results from a Phase II trial of its investigational norepinephrine and serotonin reuptake inhibitor (NSRI) 'TD-9855' in patients with fibromyalgia (FM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news